Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,410,992
  • Shares Outstanding, K 257,150
  • Annual Sales, $ 3,048 M
  • Annual Income, $ 2,097 M
  • 60-Month Beta 1.49
  • Price/Sales 18.84
  • Price/Cash Flow 70.77
  • Price/Book 10.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.95
  • Number of Estimates 7
  • High Estimate 1.07
  • Low Estimate 0.79
  • Prior Year 1.00
  • Growth Rate Est. (year over year) -5.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
199.29 +10.08%
on 11/11/19
225.66 -2.79%
on 12/09/19
+18.06 (+8.97%)
since 11/08/19
3-Month
165.23 +32.77%
on 10/02/19
225.66 -2.79%
on 12/09/19
+44.56 (+25.49%)
since 09/09/19
52-Week
151.80 +44.51%
on 12/24/18
225.66 -2.79%
on 12/09/19
+47.16 (+27.39%)
since 12/07/18

Most Recent Stories

More News
Watch for Vertex Pharm to Potentially Pullback After Gaining 1.02% Yesterday

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $222.99 to a high of $225.66. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of...

VRTX : 219.37 (-1.74%)
Vertex Pharm Rises 1.02% on Heavy Volume: Watch For Potential Pullback

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $222.99 to a high of $225.66. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of...

VRTX : 219.37 (-1.74%)
Blueprint's (BPMC) Systemic Mastocytosis Study Data Impresses

Blueprint Medicines (BPMC) posts favorable initial data from the part 1 of phase II PIONEER study on avapritinib for the treatment of patients with indolent systemic mastocytosis. Stock rises.

BAYRY : 19.0250 (-0.50%)
RHHBY : 38.3950 (-0.45%)
BPMC : 70.37 (-10.33%)
VRTX : 219.37 (-1.74%)
Gilead (GILD) Announces Positive Long-Term Data on Yescarta

Gilead (GILD) announces positive long-term data from a mid-stage study on Yescarta in adult patients with refractory large B-cell lymphoma.

GSK : 45.63 (+0.26%)
NVS : 92.53 (+0.50%)
VRTX : 219.37 (-1.74%)
GILD : 66.93 (-0.22%)
Three Stocks from the Zacks #1 Rank Uptrends Screen

Three Stocks from the Zacks #1 Rank Uptrends Screen

VRTX : 219.37 (-1.74%)
DKS : 47.59 (+3.01%)
AMAT : 56.60 (unch)
Spero Posts Preliminary Data on SPR720 for Pulmonary Disease

Spero (SPRO) reports preliminary findings from a phase I first-in-human study on SPR720, presently being evaluated for the treatment of nontuberculous mycobacterial pulmonary disease.

VRTX : 219.37 (-1.74%)
ANIK : 55.54 (-3.38%)
GH : 72.15 (-2.47%)
SPRO : 11.35 (-4.94%)
Gene Therapy the Next Best Thing: Here's Why (Revised)

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

NTLA : 16.72 (-2.22%)
VRTX : 219.37 (-1.74%)
QURE : 63.00 (-4.62%)
MGTX : 21.31 (+0.33%)
PIRS : 3.26 (-4.68%)
24.4% Return Seen to Date on SmarTrend Vertex Pharm Call (VRTX)

SmarTrend identified an Uptrend for Vertex Pharm (NASDAQ:VRTX) on October 17th, 2019 at $178.54. In approximately 2 months, Vertex Pharm has returned 24.36% as of today's recent price of $222.03.

VRTX : 219.37 (-1.74%)
Biogen's Lupus Candidate Meets Endpoint in Phase II Study

Biogen (BIIB) posts favorable top-line results from a phase II study evaluating BIIB059 for treating cutaneous and systemic lupus erythematosus. The study tastes success by achieving its main goal.

AZN : 47.77 (+0.19%)
ANIK : 55.54 (-3.38%)
BIIB : 295.55 (-1.57%)
VRTX : 219.37 (-1.74%)
Gene Therapy the Next Best Thing: Here's Why

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

NTLA : 16.72 (-2.22%)
VRTX : 219.37 (-1.74%)
QURE : 63.00 (-4.62%)
MGTX : 21.31 (+0.33%)
PIRS : 3.26 (-4.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade VRTX with:

Business Summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs...

See More

Key Turning Points

2nd Resistance Point 227.88
1st Resistance Point 223.62
Last Price 219.37
1st Support Level 217.15
2nd Support Level 214.94

See More

52-Week High 225.66
Last Price 219.37
Fibonacci 61.8% 197.45
Fibonacci 50% 188.73
Fibonacci 38.2% 180.01
52-Week Low 151.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar